Burjeel Holdings raises $324M in 11% stake IPO on Abu Dhabi exchange

Burjeel Holdings will sell an 11% stake on the Abu Dhabi Securities Exchange (ADX), raising roughly AED 1.19 billion ($324 million) in the UAE's largest private healthcare IPO since NMC Health collapsed in 2020.

The Abu Dhabi-based operator runs 82 hospitals and medical centres across the UAE and Oman. The offering, announced in September 2022, prices shares at AED 2.00 at the lower end of the AED 2.00–2.45 indicative range. That values the company at roughly AED 10.8 billion ($2.94 billion). Trading is expected to begin on 10 October 2022.

What Burjeel brings to public markets

Founded by Dr. Shamsheer Vayalil, a Kerala-born physician who built the group from a single facility in Abu Dhabi, Burjeel now operates across five brands:

• Burjeel Hospital and Burjeel Medical City (its 364-bed flagship in Abu Dhabi, competing directly with Cleveland Clinic Abu Dhabi)
• Medeor
• LLH Hospital
• Lifecare
• Tajmeel

The group reported revenue of approximately AED 4.2 billion for 2021. Abu Dhabi's mandatory health insurance framework, administered by the Department of Health – Abu Dhabi (DOH), is the primary revenue engine. The Thiqa programme for UAE nationals and the Daman scheme for expatriate workers channel insured patients to private operators across Abu Dhabi, Dubai, Sharjah, and Al Ain. Burjeel is one of the largest recipients of that volume.

Market conditions and the NMC shadow

The IPO arrives during a turbulent window for global capital markets. Rising interest rates and recession fears have suppressed valuations across sectors, and the final pricing at the bottom of the range reflects that caution. The retail tranche was oversubscribed, but institutional demand required careful management by joint global coordinators Abu Dhabi Commercial Bank, Citigroup, and EFG Hermes.

ADX has been on a listing drive throughout 2022, attracting IPOs from ADNOC subsidiaries, Borouge, and several government-linked entities as part of Abu Dhabi's economic diversification programme. Burjeel is the first major private healthcare operator to test that pipeline.

The shadow of NMC Health hangs over any UAE healthcare listing. NMC's $6.6 billion fraud, uncovered in early 2020, destroyed investor confidence in the sector and forced years of restructuring. Burjeel's prospectus will face scrutiny that a healthcare operator would not have encountered before that scandal. Governance disclosures, related-party transactions, and debt structures will receive forensic attention from institutional investors who remember what opaque balance sheets can conceal.

What operators and regulators should watch

A successful debut would signal that public markets are open again for UAE healthcare assets. Two operators are positioned to follow:

• Pure Health, Abu Dhabi's government-backed healthcare consolidator, has been assembling an acquisition portfolio that could eventually seek its own public listing.
• Aster DM Healthcare, which operates 29 facilities across the UAE, has explored separating its GCC and India businesses, a move that could produce another ADX-listed healthcare stock.

For CFOs at competing hospital groups, Burjeel's public financials will provide the first transparent benchmark for revenue per facility, operating margins, and patient volume in the Abu Dhabi market. That data has been difficult to obtain from private operators.

For DOH regulators, a publicly listed operator with quarterly disclosure requirements adds market discipline to Abu Dhabi's healthcare sector. Investors will demand the same quality and compliance metrics that DOH already monitors.

Burjeel shares are expected to begin trading on ADX on 10 October 2022.